{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T22:18:01Z","timestamp":1773872281707,"version":"3.50.1"},"reference-count":28,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2008,3,4]],"date-time":"2008-03-04T00:00:00Z","timestamp":1204588800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Human Psychopharmacology"],"published-print":{"date-parts":[[2008,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Objective<\/jats:title><jats:p>To test association of dopamine receptor D3 (DRD\u20103) gene polymorphisms with olanzapine response in genetic samples from a registration phase clinical trial.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Eighty\u2010eight acutely ill patients with schizophrenia or schizoaffective disorder were genotyped for ser\u20109\u2010gly (rs6280) and 23 other polymorphisms within the DRD\u20103 gene. Allelic association of clinical response (mean baseline\u2010 to\u2010endpoint reduction in Positive and Negative Syndrome Scale [PANSS] total and subscores) over 6 weeks of olanzapine treatment was assessed using repeated measures analysis of variance.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Ser\u20109\u2010gly genotypes were associated with differences in PANSS total score improvement from baseline to 6 weeks (<jats:italic>p<\/jats:italic>\u2009=\u20090.021). This association was most notable for improvement in positive symptoms (<jats:italic>p<\/jats:italic>\u2009=\u20090.0001), with patients with gly\/gly genotype significantly more responsive. More patients with the gly\/gly genotype had greater positive symptom remission (endpoint rating of minimal or none on all PANSS positive items, 39.1%) compared with patients with gly\/ser and ser\/ser genotypes (13.8%;<jats:italic>p<\/jats:italic>\u2009=\u20090.033). DRD\u20103 polymorphisms in disequilibrium with ser\u20109\u2010gly were also significantly associated with greater positive symptom improvement (<jats:italic>p<\/jats:italic>\u2009=\u20090.0009\u20130.021), and one not in complete linkage disequilibrium, with lesser improvement (<jats:italic>p<\/jats:italic>\u2009=\u20090.027).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Gly\/gly DRD\u20103 genotype predicted statistically and clinically significantly better acute positive symptom reduction compared with other ser\u20109\u2010gly genotypes in patients treated with olanzapine. Copyright \u00a9 2008 John Wiley &amp; Sons, Ltd.<\/jats:p><\/jats:sec>","DOI":"10.1002\/hup.930","type":"journal-article","created":{"date-parts":[[2008,3,4]],"date-time":"2008-03-04T13:47:01Z","timestamp":1204638421000},"page":"267-274","source":"Crossref","is-referenced-by-count":31,"title":["Dopamine receptor D3 genotype association with greater acute positive symptom remission with olanzapine therapy in predominately caucasian patients with chronic schizophrenia or schizoaffective disorder"],"prefix":"10.1002","volume":"23","author":[{"given":"David H.","family":"Adams","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandra","family":"Close","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Farmen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"AnnCatherine M.","family":"Downing","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alan","family":"Breier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John P.","family":"Houston","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2008,3,4]]},"reference":[{"key":"e_1_2_1_2_1","first-page":"57","volume-title":"The Genetics Of Human Populations","author":"Cavalli\u2010Sforza LL","year":"1999"},{"key":"e_1_2_1_3_1","doi-asserted-by":"publisher","DOI":"10.1136\/jmg.29.12.858"},{"key":"e_1_2_1_4_1","doi-asserted-by":"publisher","DOI":"10.1159\/000154327"},{"key":"e_1_2_1_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1096-8628(19980710)81:4<318::AID-AJMG8>3.0.CO;2-P"},{"key":"e_1_2_1_6_1","first-page":"921","article-title":"Maximum\u2010likelihood estimation of molecular haplotype frequencies in a diploid population","volume":"12","author":"Excoffier L","year":"1995","journal-title":"Mol Biol Evol"},{"key":"e_1_2_1_7_1","unstructured":"GaudermanWJ MorrisonJM.QUANTO 1.1: a computer program for power and sample size calculations for genetic\u2010epidemiology studieshttp:\/\/hydra.usc.edu\/gxe."},{"key":"e_1_2_1_8_1","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1997.01830150047009"},{"key":"e_1_2_1_9_1","doi-asserted-by":"publisher","DOI":"10.1136\/jmg.2004.020941"},{"key":"e_1_2_1_10_1","unstructured":"International HapMap Project.HapMap Genotype Databasehttp:\/\/www.hapmap.org."},{"key":"e_1_2_1_11_1","doi-asserted-by":"publisher","DOI":"10.1097\/00041444-200303000-00001"},{"key":"e_1_2_1_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1359-6446(05)03491-4"},{"key":"e_1_2_1_13_1","first-page":"179","article-title":"Automated genotyping using the DNA MassArray technology","volume":"187","author":"Jurinke C","year":"2002","journal-title":"Methods Mol Biol"},{"key":"e_1_2_1_14_1","volume-title":"Positive and Negative Syndrome Scale (PANSS) Manual","author":"Kay SR","year":"1992"},{"key":"e_1_2_1_15_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.jcp.0000150226.84371.76"},{"key":"e_1_2_1_16_1","doi-asserted-by":"publisher","DOI":"10.1038\/ng1071"},{"key":"e_1_2_1_17_1","doi-asserted-by":"publisher","DOI":"10.1006\/bbrc.1996.1296"},{"key":"e_1_2_1_18_1","doi-asserted-by":"publisher","DOI":"10.2165\/00023210-200216050-00004"},{"key":"e_1_2_1_19_1","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/S0022-3565(24)35260-7","article-title":"S18327 (1\u2010[2\u2010[4\u2010 (6\u2010fluoro\u20101,2\u2010benxisoxazol\u20103\u2010yl)piperid\u20101\u2010yl]ethyl]3\u2010phenyl imidazolin\u20102\u2010one), a novel, potential antipsychotic displaying marked antagonist properties at alpha(1)\u2010 and alpha(2)\u2010 adrenergic receptors: II. Functional profile and a multiparametric comparson with haloperidol, clozapine, and 11 other antipsychotic agents","volume":"292","author":"Millan MJ","year":"2000","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_2_1_20_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.105.089326"},{"key":"e_1_2_1_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.euroneuro.2004.07.001"},{"key":"e_1_2_1_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1460-9568.2004.03774.x"},{"key":"e_1_2_1_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0924-977X(99)00044-9"},{"key":"e_1_2_1_24_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF02346178"},{"key":"e_1_2_1_25_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-002-1084-4"},{"key":"e_1_2_1_26_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajmg.b.20045"},{"key":"e_1_2_1_27_1","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.154.4.457"},{"key":"e_1_2_1_28_1","doi-asserted-by":"publisher","DOI":"10.1159\/000080958"},{"key":"e_1_2_1_29_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.mp.4000376"}],"container-title":["Human Psychopharmacology: Clinical and Experimental"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fhup.930","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hup.930","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,28]],"date-time":"2025-01-28T22:16:17Z","timestamp":1738102577000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/hup.930"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,3,4]]},"references-count":28,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2008,6]]}},"alternative-id":["10.1002\/hup.930"],"URL":"https:\/\/doi.org\/10.1002\/hup.930","archive":["Portico"],"relation":{},"ISSN":["0885-6222","1099-1077"],"issn-type":[{"value":"0885-6222","type":"print"},{"value":"1099-1077","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,3,4]]}}}